Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANOSHINE-D3 (cholecalciferol)
- Development stage
- Unknown
- Lead developer
- Adorshea Bioceutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NANOSHINE-D3 is a cholecalciferol (Vitamin D3) supplement developed by Adorshea Bioceutics, primarily indicated for the treatment and prevention of Vitamin D deficiency. Formulated as a nano-emulsion, it is designed to enhance the bioavailability and absorption of the fat-soluble vitamin. Cholecalciferol acts as an agonist of the Vitamin D receptor (VDR), facilitating the intestinal absorption of calcium and maintaining adequate serum calcium and phosphate concentrations to enable normal mineralization of bone.
- Brand names
- NANOSHINE-D3NANOSHINE-D-3NANOSHINE-D 3
- Other names
- Vitamin D3colecalciferol
02
Targets
RXRA (Retinoid X receptor alpha)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on NANOSHINE-D3 (cholecalciferol).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANOSHINE-D3 (cholecalciferol).